THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)

The article considers the results of an international multicenter randomized clinical trial of the efficacy and safety of the brand-name drug rituximab (MabThera), a monoclonal antibody against CD20 antigen of B cells, and its biosimi-lar drug (Acellbia®) (the BIORA study) in patients with rheumatoi...

Full description

Bibliographic Details
Main Authors: E. L. Nasonov, E. V. Zonova, O. N. Ivanova, L. A. Knyazeva, V. I. Mazurov, R. R. Samigullina, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, A. E. Sizikov, D. G. Krechikova, N. A. Petrochenkova, Yu. S. Shapovalova, N. S. Soroka, S. I. Pimanov, A. M. Pristrom, E. V. Kunder, E. V. Chernyaeva, A. V. Eremeeva, R. Ivanov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2016-12-01
Series:Научно-практическая ревматология
Subjects:
rheumatoid arthritis
rituximab
biosimilar drug
Online Access:https://rsp.mediar-press.net/rsp/article/view/2292

Internet

https://rsp.mediar-press.net/rsp/article/view/2292

Similar Items